Glaukos Corp (GKOS) Stock Analysis
Verdict: HOLD
High-growth iDose TR adoption justifies a premium valuation, but aggressive insider selling and -36% operating margins demand a pullback.
Investment score: 64/100
Analysis as of
Is Glaukos Corp stock worth reviewing? AI model thesis
Glaukos is a high-conviction growth play in ophthalmology with superior gross margins, currently undergoing a technical correction.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Glaukos Corp opportunities and risks
What speaks for GKOS
- iDose TR Product Ramp
What speaks against GKOS
- Heavy Insider Selling Transaction Activity
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GKOS | n/a | 12.8x | n/a | 78.1% | -34.3% | -0.3% |
| PEN | 75.5x | 8.9x | 60.7x | 67.4% | 11.8% | 1.6% |
| GMED | 19.6x | 3.7x | 12.4x | 67.9% | 18.9% | 5.3% |
| PODD | 35.8x | 3.7x | 19.9x | 71.0% | 10.4% | 3.8% |
| BAX | n/a | 0.9x | 23.6x | 30.1% | -9.7% | 7.2% |
| MASI | 122.3x | 6.0x | 28.2x | 61.7% | 4.9% | 2.2% |
| Peer median | 35.8x | 3.7x | 23.6x | 67.4% | 10.4% | 3.8% |
Frequently asked questions about Glaukos Corp (GKOS)
Is GKOS stock a good investment?
The cached TradeMates AI model rates Glaukos Corp as HOLD with an investment score of 64/100. Glaukos is a high-conviction growth play in ophthalmology with superior gross margins, currently undergoing a technical correction. This is algorithmic model output, not personal investment advice.
Is GKOS stock a buy?
The TradeMates model verdict for GKOS is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.